Konstantinovsky Irina 4
4 · Horizon Therapeutics Public Ltd Co · Filed Jan 8, 2021
Insider Transaction Report
Form 4
Konstantinovsky Irina
EVP, Chief Human Resources Off
Transactions
- Sale
Ordinary Shares
2021-01-06$71.63/sh−626$44,840→ 112,717 total - Sale
Ordinary Shares
2021-01-06$75.28/sh−16,547$1,245,658→ 86,499 total - Sale
Ordinary Shares
2021-01-06$73.30/sh−2,200$161,260→ 110,517 total - Sale
Ordinary Shares
2021-01-06$74.30/sh−7,471$555,095→ 103,046 total
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.33 to $72.27 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.67 to $73.66 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.69 to $74.68 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.70 to $75.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.